04.10.2018
- Lonza and Clovis Oncology have opened a new, dedicated production train for Rubraca (rucaparib), at Lonza’s Visp site in Switzerland. Rubraca is Clovis’ US- and EU-approved drug...
31.10.2012
- Swiss drugs industry supplier Lonza plans to cut 500 jobs, including 400 at its main plant in Visp, to improve profitability as it grapples with price pressures, a strong Swiss...
